Last Updated on 18 August 2025 by BIZNAMA NEWS
Posted on .
Baar, Switzerland
Extrovis AG, a global pharmaceutical company focused on research-driven innovation, and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”), today announced the launch of Fluorouracil Cream, 0.5%, an authorized generic and therapeutic equivalent of Carac® (fluorouracil cream) 0.5%, in the US market, approved by the U.S. Food and Drug Administration (USFDA).
Manufactured in Texas at one of Extrovis’ facilities, Dr. Reddy’s Fluorouracil Cream, 0.5%, is indicated for the topical treatment of multiple actinic or solar keratoses of the face and anterior scalp.
“This product generic launch marks a key milestone in our commitment to increasing patient access and long-term value creation for the U.S. healthcare system. Our partnership with Dr. Reddy’s helps ensure that patients and healthcare providers in the United States have continued access to a high-quality and cost-effective product,” said Hans R. Kamma Co-CEO and Chief Strategy Officer of Extrovis AG.
“Dr. Reddy’s brings deep expertise in commercialization and distribution within the U.S. market,” added Raghavendra Rao PV, Chief Financial Officer of Extrovis AG. “This collaboration is aligned with our mission to strengthen pharmaceutical supply chains and serve public health needs responsibly.”
The partnership reinforces Extrovis’ strategy to extend the reach of its therapeutics while advancing long-term affordability and sustainability in healthcare.
Dr. Reddy’s Fluorouracil Cream, 0.5%, is supplied in a 30-gram tube for topical use only. Please click here to see the full prescribing information.